NASDAQ
14.51USD
+0.01 (+0.07%)
We have scored 43 news catalysts on Ultragenyx Pharmaceutical Inc. (RARE) over the past 12 months. The biggest single-day move next to one of them came Sep 3, 2026, when RARE closed −44.0%: “Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial”. Coverage across the window leans negative (average ticker sentiment −0.44). Most of the impact sits in price momentum and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.4B
P/E
—
EPS
—
Beta
0.32
52W range
12.73-39.89
Day range
14.07–15.07
Open
14.68
Prev close
14.50
Volume
13.3M
Avg volume
3.1M
Dividend
0.00
IPO
2014-01-31
Analysts publish price targets on RARE, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
18 analyst price targets from $16 to $83
as of 2026-09-14
The market is 54% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Ultragenyx Pharmaceutical Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Ultragenyx Pharmaceutical Inc., taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for RARE: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
The price at $14.51 sits at the absolute bottom of 18 published models, 54% below the median target of $31, showing the market has fully absorbed the recent clinical failures and refuses to pay for any recovery.
What the disagreement turns on
Whether the Angelman syndrome Phase 3 data and the pending FDA decisions for DTX401/UX111 can restore enough value to bridge the massive gap between $14.51 and the $31 median target, a question that wired data on unit volumes cannot settle because the outcome hinges on binary clinical and regulatory events.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
